Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome. World J Gastroenterol 2021; 27(22): 3109-3120 [PMID: 34168412 DOI: 10.3748/wjg.v27.i22.3109]
Corresponding Author of This Article
Ken Sugimoto, MD, PhD, Associate Professor, First Department of Medicine, Hamamatsu University of School of Medicine, 1-20-1 Handayama Higashi-ku Hamamatsu, Hamamatsu 431-3192, Japan. sugimken@hama-med.ac.jp
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 14, 2021; 27(22): 3109-3120 Published online Jun 14, 2021. doi: 10.3748/wjg.v27.i22.3109
Table 1 Baseline characteristics of patients
Characteristics
n = 47
Age (yr), mean (range) ± SD
44.9 (16-78) ± 18.7
Male/female, n (%)
38/9 (80.9/10.6)
Disease duration (yr), mean (range) ± SD
3.2 (0.1-42) ± 7.0
Disease extent, n (%)
Extensive colitis
42 (89.4)
Left sided colitis
5 (10.6)
CAI (Rachmilewitz index) mean (range) ± SD
11.0 (7-17) ± 2.7
MES
MES 2
9 (19.1)
MES 3
38 (80.9)
Medication at study, n (%)
Oral 5-ASA
21 (44.7)
Suppository 5-ASA
7 (14.9)
Systemic steroids
28 (59.6)
Immunomodulators
10 (21.3)
Biologics
11 (23.4)
History of biologics, n (%)
12 (25.5)
Time to high trough level (d), mean (range) ± SD
8.1 (0-46) ± 7.5
Table 2 Comparison between the failure and remission groups before tacrolimus induction
Characteristics
Remission (n = 30)
Failure (n = 17)
P value
Age (yr), mean ± SD
41.33 ± 16.8
51.1 ± 20.7
0.084
Male/female, n (%)
23/7 (76.7 / 23.3)
15/2 (88.2/11.8)
0.455
Disease duration (yr), mean ± SD
2.0 ± 2.8
5.46 ± 10.9
0.098
Disease extent, n (%)
Extensive colitis
27 (90.0)
15 (88.2)
1
Left sided colitis
3 (10.0)
2 (11.8)
CAI (Rachmilewitz index), mean ± SD
10.7 ± 2.4
11.7 ± 2.9
0.221
MES
MES 2
6 (20.0)
3 (17.6)
1
MES 3
24 (80.0)
14 (82.4)
Medication at study, n (%)
Oral 5-ASA
16 (53.3)
5 (29.4)
0.138
Suppository 5-ASA
5 (16.7)
2 (11.8)
1
Systemic steroids
19 (63.3)
9 (52.9)
0.546
Immunomodulators
6 (20.0)
4 (23.5)
1
Biologics
6 (20.0)
5 (29.4)
0.493
History of biologics, n (%)
6 (20.0)
6 (35.3)
0.306
Time to high trough level (d), mean ± SD
7.9 ± 8.1
8.5 ± 6.4
0.773
Table 3 Comparison of biological data before and after tacrolimus induction
Biological data
Remission (n = 30)
Failure (n = 17)
P value
Serum Alb at week 0 (g/dL)
2.83 ± 0.68
2.81 ± 0.72
0.897
Serum Alb at week 1 (g/dL)
2.94 ± 0.61
2.85 ± 0.78
0.651
Serum Alb at week 2 (g/dL)
3.29 ± 0.57
2.81 ± 0.73
0.015
Serum CRP at week 0 (mg/dL)
5.58 ± 5.75
5.44 ± 5.45)
0.933
Serum CRP at week 1 (mg/dL)
0.88 ± 2.29
1.12 ± 1.51
0.696
Serum CRP at week 2 (mg/dL)
0.54 ± 1.50
1.17 ± 1.63
0.191
Hb at week 0 (g/dL)
11.2 ± 1.90
11.32 ± 2.06
0.871
Hb at week 1 (g/dL)
10.65 ± 1.60
11.15 ± 1.77
0.326
Hb at week 2 (g/dL)
10.78 ± 1.71
10.89 ± 1.88
0.837
WBC at week 0 (/μL)
8660.00 ± 4498.65
8846.47 ± 3876.21
0.887
WBC at week 1 (/μL)
5958.00 ± 2444.20
6618.24 ± 2201.22
0.362
WBC at week 2 (/μL)
5473.00 ± 2095.78
6672.35 ± 2154.37
0.069
Table 4 Comparison of biological data ratio after tacrolimus induction
Rate of biological data
Remission (n = 30)
Failure (n = 17)
P value
Week 1/week 0 Alb ratio
1.05 ± 0.14
1.02 ± 0.13
0.429
Week 2/week 0 Alb ratio
1.19 ± 0.20
1.02 ± 0.16
0.003
Week 1/week 0 CRP ratio
0.28 ± 0.49
1.28 ± 3.80
0.159
Week 2/week 0 CRP ratio
0.16 ± 0.23
1.42 ± 4.28
0.112
Week 1/week 0 Hb ratio
0.96 ± 0.13
1.01 ± 0.18
0.315
Week 2/week 0 Hb ratio
0.97 ± 0.13
0.98 ± 0.14
0.892
Week 1/week 0 WBC ratio
0.77 ± 0.32
0.84 ± 0.33
0.520
Week 2/week 0 WBC ratio
0.72 ± 0.30
0.86 ± 0.40
0.194
Table 5 Multivariate analysis for predicting failure during 3 mo after tacrolimus induction
Variable
Univariate analysis
Multivariate analysis
HR
95%CI
P value
HR
95%CI
P value
Week 2/week 0 Alb ratio ≤ 1
3.632
1.396-9.445
0.008
7.195
2.011-25.74
0.002
Age
1.026
0.998-1.055
0.072
1.009
0.976-1.042
0.599
Sex (male)
2.139
0.489-9.362
0.313
2.420
0.435-13.45
0.313
Disease extent (extensive colitis)
1.062
0.243-4.640
0.937
4.665
0.554-39.30
0.157
MES 3
1.188
0.341-4.137
0.787
0.462
0.142-1.503
0.200
Medication
Oral 5-ASA
0.450
0.158-1.277
0.133
0.578
0.191-1.744
0.331
Suppository 5-ASA
0.652
0.149-2.853
0.570
0.247
0.035-1.744
0.161
Systemic steroids
0.729
0.281-1.890
0.515
0.636
0.193-2.094
0.457
Immunomodulators
1.152
0.375-3.543
0.805
1.516
0.391-5.885
0.548
Biologics
1.400
0.493-3.978
0.527
0.924
0.173-4.920
0.926
Citation: Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome. World J Gastroenterol 2021; 27(22): 3109-3120